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(Received for publication August 9, 1993) The chemotherapeutic significance of oral antibacterial agents is evidenced by their ability to generate annual sales of several billion dollars.
Although many useful agents are currently available, the search for new, more potent compoundswith broader spectra of activity continues. Our own efforts in this area have been influenced by the activity and pharmacokinetic properties of FK-482 (I).1 '2) FK-482 is characterized by a (Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido group at C-7 of a 3-vinyl cephalosporin nucleus. nucleus has previously been shownto support oral bioavailability with other side chains attached to the C-7 nitrogen.3~5) Thus, we chose to append the (Z)-2-(2-aminothiazol-4-yl)- 2-hydroxyiminoacetyl group to the 3-chlorocephalosporin and 3-chloro-lcarba-1 -dethiacephalosporin nuclei since they serve as the foundation for the well known oral agent Ceclor (cefaclor) and the recently introduced Lorabid (loracarbef).
Experimental
All reactions described herein were performed under an inert atmosphere of dry nitrogen in flame-dried glassware unless otherwise noted. All reagents were used as supplied unless stated otherwise. Melting points were recorded on a Thomas-Hoover apparatus and are uncorrected. *H NMR spectra were recorded at 300MHzwith a General Electric QE-300 instrument, at 270 MHz with a Brucker W-Minstrument and at 90MHz with a JEOL FX-90 instrument. Chemical shifts are recorded in parts per million (S) relative to tetramethylsilane. IR spectra were recorded on a UV (EtOH) 248nm (e=29,600).
To a solution of4a (1.45g, 1.42mmol) in CH3CN
Present Address: La Jolla Pharmaceutical Co., 6455 Nancy Ridge Dr., San Diego, CA 92009, U.S.A. (140ml) and H2O (45ml) at 40°C was added NaHCO3(14.28 g, 170mmol). The suspension was stirred for 1 minute, then Na2S2O4 (9.86g, 56.7 mmol) was added as a solid over 2 minutes with gas evolution. After 6 minutes stirring, the reaction was poured into H2O -CH2C12 and the pH was lowered to 3 with concentrated HC1. The aqueous layer was extracted with CH2C12, the organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The crude product was purified by flash chromatography on silica gel (2.5% AcOH-EtOAc) to yield 740mg of 5a (53%) as a yellow solid: *H Preparation of (7S,6i?)
To a solution of5b (410mg, 0.47mmol) in THF (3ml) was added 50% formic acid (3ml) and the reaction was stirred at 45°C for 4 hours. The reaction was diluted with CH3CNand concentrated. 
Pharmacology
Male Sprague-Dawley rats were dosed intravenously with test compounds at 20mg/kg in 0.9% saline. Dosing and blood sampling were carried out through an indwelling jugular vein cannula, thus permitting serial sampling from individual rats. Plasma levels were determined from samples col-lected over a 6-hour time course. Male CD-I mice were dosed both orally and intravenously with test compound at 20mg/kg in 0.9% saline. The 04 hours cumulative urinary recovery was collected in 0.1 m sodium citrate buffer, pH 6.5, from animals placed in metabolism cages. Plasma and urine samples were stored at -70°C prior to analysis. Oral bioavailability was calculated as the oral/ intravenous ratio of antibacterial activity recovered in the urine following a 20mg/kg dose. Antibiotic concentrations were determined with an agar well diffusion assay (bioassay) employing Escherichia coli (ATCC4157) as the bacterial test strain. Standard curves were generated from rat plasma spiked with the compound under study. Urine samples were analyzed by comparison to a standard curve prepared in 0.1 m sodium citrate buffer, pH 6.5. Urine samples were diluted with citrate buffer so that the drug concentration would fall into the range of the standard curve.
Results and Discussion
Preparation of the two compoundswas accomplished as shown in Scheme 1. Thus, acylation of the appropriate nucleus followed by removal of the protecting groups provided the desired products.
Both 6a and 6b exhibited potent Gram-positive and
Gram-negative antibacterial activity as determined by an agar dilution method6) and summarized in Table 1 . Unfortunately, the compounds were inactive against Pseudomonas. a Oral bioavailability = urinary recovery (po)/urinary recovery (iv)
The pharmacokinetic profiles of the 3-chloro derivatives 6a and 6b were evaluated in male
Sprague-Dawley rats following intravenous administration. The drug concentration at 30 minutes was
The oral absorption of compounds 1, 6a and 6b
was tested experimentally in CD-I mice. Oral bioavailability was calculated as the po/iv ratio of antibacterial activity recovered in the urine following a 20mg/kg dose. The results, shown in Table 2 , demonstrate that the oral bioavailability of the 1-carbacephalosporin analogue 6b, while relatively low, is greater than that of6a and 1.
This observation combined with the well documented stability of the 1-carbacephalosporins relative to their 1-sulfur counterparts7) has prompted us to select 6b for more detailed studies. In addition, esters of these types of compounds have been demonstrated to exhibit enhanced oral bioavailability.5'8~1 1} Thus, our intention is to prepare such ester prodrugs of 6b in the hope of obtaining well-absorbed antimicrobial agents for clinical studies. The results of these continuing studies will be reported in due course.
